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The aim of this paper is to review available data about drugs for preventing preterm labour. Tocolytic therapy includes β
adrenergic receptor agonists, NO donors, magnesium sulphate, prostaglandin-synthase inhibitors, oxytocin receptor antagonists,
calcium-channel blockers, progesterone, 17-α-hydroxyprogesterone caproate, and antibiotics. Their speciﬁc eﬀects on myometrial
contractility, their safety, their eﬃciency, and side eﬀects proﬁle for the mother and the fetus are presented. The main question of
why and for what reasons tocolysis should be administrated is discussed.
1.Introduction
Preterm delivery is deﬁned by a birth occurring before 37
weeks of gestation or before 259 days from the last menstrual
period. Prematurity is multifactorial and its incidence has
increasedduringthelastdecadeinmostoccidentalcountries,
probably due to increased risk factors responsible for elective
prematurity [1–3].
The mechanisms for preterm labour are still unclear. It
could be associated either with a premature activation of the
physiological contracting process or with a pathological fac-
tor responsible for uterine contractions, leading to preterm
delivery [1–3].
Among identiﬁed pathways for preterm labour, there
are uterine overdistension due to multiple pregnancies or
polyhydramnios, placental ischaemia, cervical disease, im-
munologic and allergic phenomena, decidual or retropla-
cental haemorrhage, fetal endocrine activation intrauterine
infections, and inﬂammatory processes. Elective prematurity
duetomaternalorfoetalconditionsisbecomingasigniﬁcant
cause [1–4].
Tocolytic drugs have been available for several decades
but their actions are directed toward the eﬀects and not the
causes of preterm labour [1, 3, 5].
Therapeutic strategies available in the literature for stop-
pingpretermlabourarediscussedinthispaper.Theireﬃcacy
depend on an early and accurate diagnosis of the condition,
thefetalﬁbronectin,andcervicallengthultrasonography[2].
Drugs safety and side eﬀectproﬁle is a major concern not
only for the pregnant women but also for the foetus [4–6].
In some clinical conditions such as abruptio and chorioam-
nionitis, inhibition of uterine contractions and birth delay
may be more harmful in terms of outcome and should
be avoided [2, 3]. Another concern is the administration
route and the optimal range of gestational age for these
treatments [5].
Tocolysis aims not only to inhibit uterine contractions
but also to allow a safe transfer of the pregnant patient to a
tertiary care centre. It gives the opportunity to administrate
corticosteroids for preventing neonatal risks associated with
prematurity [5–7].
2. Mechanismsof Tocolysis
Myometrial contractility is a complex process based on
myocytes function. It involves the presence of hormonal
receptors, ions channels, intercell gap junctions, and reg-
ulatory proteins such as oxytocin, endothelin, tachykinin,
and angiotensin [8, 9]. The increase of intracellular calcium
concentration is essential for the uterine smooth muscle
contraction [9].
As shown on Figure 1, uterine relaxation may be
obtained by interfering with an intracellular messenger
responsible for contractile proteins eﬀects: β adrenergic
receptor agonists, nitric oxide (NO) donors, magnesium2 Journal of Pregnancy
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Figure 1: Mechanisms of action for tocolytics.
sulphate and calcium channel blockers are tocolytic drugs
aiming to this [1, 2, 6, 9]. Another pathway involves the inhi-
bition of contracting factors synthesis or eﬀect. Atosiban, an
oxytocin receptor antagonist and prostaglandin-synthetase
inhibitors have this eﬀect by interfering with endogenous
myometrial stimulators [1, 2, 6, 9].
3. Typesof Tocolytic Treatment
3.1. β Adrenergic Receptor Agonists. Selective β 2 agonists
such as ritodrine and salbutamol have been used in clinical
practice for preterm labour since the 1980s. These drugs
impair intracellular cyclic AMP concentration and facilitate
myometrial relaxation [9, 10]. Randomized controlled stud-
ies and meta-analysis reported that these agents were more
eﬃcient than placebo for delaying preterm birth for two
days.Unfortunately,nobeneﬁtforlong-term(tocolyticeﬀect
restricted to 7 days) and perinatal mortality and morbidity
rate was found [5, 10, 11]. Moreover, even with selec-
tive β 2 adrenergic receptor agonists, there are signiﬁcant
maternal side eﬀects reported such as tachycardia, dyspnoea,
hypokalemia, hyperglycemia, and chest pain [5, 6, 9–12]. In
conclusion,despitetheireﬃciency,β 2agonists’safetyproﬁle
is a real concern responsible for therapy discontinuation and
choosing alternative tocolytic drugs.
3.2. NO Donors. NO is a powerful vasodilator synthesized
during an amino acid oxidation process catalysed by NO
synthase. It is present in myometrial cells and increases
cGMP content by interaction with guanylyl cyclase. There is
aspeciﬁclinkbetweenNOproductionanduterinerelaxation
[8, 9].
Transdermal nitroglycerin administration has been used
inpretermlabourbutonlyinsmallseries.Itwasassociatedto
ab e t t e rt o c o l y t i ce ﬀect than placebo on delaying delivery for
two days. Its eﬀect was similar to ritodrine [2–5]. As there
is no large randomized studies available, NO is not used in
clinical routine.
3.3. Magnesium Sulphate. The relaxant eﬀect of Magnesium
sulphate in vitro and in vivo on human uterine contractility
has been widely reported. As magnesium is a calcium
antagonist, it decreases calcium intracellular concentration
and inhibits contraction process [2, 4, 9]. However, in 2002,
a meta-analysis based on 881 patients did not evidence any
beneﬁt of Magnesium sulphate administration over placebo
use in preterm labour [13]. As the drug is crossing the
placenta, there were concerns about fetal safety. An increased
risk of perinatal death and neonatal adverse eﬀects including
neurological and metabolic disorders were reported in some
trialsusingMagnesiumsulphatetreatmentathighdosage[6,
13]. It can also aﬀect maternal neuromuscular system. Over
a serum concentration of 9mg/dL, there is a high toxicity
risk resulting in respiratory depression and disappearance of
reﬂexes. There is no evidence any more to recommend this
drug as a ﬁrst-line tocolytic agent [2, 6, 13, 14].
However, when administered prophylactically at low
dose, it was reported to have a neonatal neuroprotective
eﬀect in a randomized multicentre trial [15] but this eﬀect
should be conﬁrmed in the next future on large randomised
controlled studies [16].
3.4. Prostaglandin-Synthase Inhibitors. Prostaglandin-syn-
thase or cyclooxygenase (COX) isoforms COX-1 and -2 are
essential enzymes for converting arachidonic acid to pros-
taglandins. Prostaglandins are well-known uterine con-
traction inducer by enhancing myometrial gap junction
and increasing intracellular calcium concentration [2, 4, 5,
9]. Indomethacin, a nonspeciﬁc COX inhibitor, has been
reported in studies and in a recent meta-analysis to be an
eﬃcient tocolytic drug compared to placebo, signiﬁcantly
delaying preterm delivery [11]. It can be administrated
rectally or orally. Its use should be restricted in duration and
limitedtopregnanciesbelow32weeksbecauseoffetalductus
arteriosus closure risk and decreased urine production
responsible for oligohydramnios [3, 5, 6, 17]. These treat-
ments also have maternal side eﬀects including gastric ulcer
or asthma recurrence [3, 5, 6]. COX-2 inhibitors such as
nimesulide or rofecoxib have been studied in animal but
not yet in humans and are not actually recommended for
preventing preterm labour in clinical practice [18]. In
conclusion, indomethacin is an eﬃcient tocolytic drug with
no serious adverse drug reaction and is indicated for short-
term eﬀect during the second trimester of pregnancy.
3.5. Oxytocin Receptor Antagonists. These agents are in
competition with the myometrial and decidual oxytocin
receptors. The only drug used in clinical practice is atosi-
ban. It blocks in a reversive manner the intracytoplasmic
calcium release associated with contractions and downreg-
ulates prostaglandin synthesis [2, 9]. A ﬁrst multicentric
randomised trial comparing atosiban and ritodrine demon-
strated a similar tocolytic eﬀect but fewer adverse eﬀects
with atosiban [4, 6]. A meta-analysis published in 2005
reported no beneﬁt in terms of preterm delivery rate and
neonatal outcome in 1695 patients treated either by atosiban
or placebo [19]. This study was responsible for the FDA
nonapproval of atosiban in the USA. However, in Europe,
many studies were carried out and did not conﬁrm it.Journal of Pregnancy 3
Atosiban is widely used in clinical practice because of its low
side eﬀects proﬁle [5, 6]. A german meta-analysis based on
6 randomised trials, among them 3 double blind studies,
conﬁrmed a similar tocolytic action for atosiban and β
adrenergic receptor agonists. A signiﬁcantly low incidence
of adverse eﬀects is reported. Moreover, a lower cost saving
in terms of hospital length and extra tests for excluding mor-
bidity causes is found for the atosiban treated patients when
compared to continuous fenoterol administration controls
[12]. In conclusion, atosiban seems to be an adequate thera-
peutic choice for eﬀective tocolysis with a low maternal and
fetal adverse eﬀects proﬁle.
3.6. Calcium-Channel Blockers. These agents are interfering
with the calcium ions transfer through the myometrial cell
membrane. They decrease intracellular free calcium concen-
tration and induce myometrial relaxation [2–4].
Nifedipine is the most commonly used drug for preterm
labour inhibition at a daily dose of 30–60mg daily. Ran-
domised controlled trials report a similar tocolytic eﬀect
for nifedipine compared with β adrenergic receptor agonists
[20]. Unfortunately, there is no placebo-controlled studies
available to conﬁrm it. A Cochrane Database review meta-
analysis published in 2003, reported a decreased number
of deliveries within 7 days following treatment and also, a
reduced incidence of neonatal respiratory distress syndrome
[21]. A recent systematic review based on 26 trials and 2179
patients conﬁrms a higher eﬃciency and a lower side eﬀects
incidence in the nifedipine group compared to β adrenergic
receptor agonists-treated patients [22]. These data conﬁrm
that nifedipine is a eﬃcient tocolytic agent, with an easy oral
route of administration, few side eﬀects, and a low neonatal
complications rate. However, it should be used with caution
in patients with compromised cardiovascular condition as
they may be at risk of pulmonary oedema and cardiac failure
[5].
3.7. Progesterone and 17-α-Hydroxyprogesterone Caproate.
Progesterone is a steroid hormone secreted by the corpus
luteum and by the placenta after 8 weeks of gestation. It
has a physiological eﬀect on uterine quiescence mediated
by a direct eﬀect on intracellular calcium concentration and
prostaglandin synthesis [1, 2, 5, 9]. Several randomised trials
reported a signiﬁcantly reduced incidence of preterm birth
in patients at risk treated either with weekly intramuscular
17-α-hydroxy progesterone caproate [23] or daily vaginal
micronized progesterone [24, 25]f r o m2 4t o3 4w e e k s .B u t
these treatments showed no beneﬁt in terms of perinatal
mortality and morbidity [2, 5, 23–25]. The vaginal route
of progesterone administration is associated with less side
eﬀects such as sleepiness and headaches [4, 5]. Although
these treatments seem eﬀective in patients with previous
history of preterm birth or with a short cervix, it is essential
to collect more data in large randomised controlled trials for
conﬁrming its potential beneﬁt in the prevention of preterm
delivery.
3.8. Antibiotics. Infection is one of causal factors of preterm
labour with an incidence of 20–40%, especially before 30
weeks [1, 2]. Antibiotics use for preventing preterm labour
has been largely studied [5, 28–30]. In the presence of
preterm labour with intact membranes, the prophylactic
administration of antibiotics is not recommended as there
is little evidence of beneﬁts [28]. But if there is a preterm
rupture of the membranes (PROM), a meta-analysis based
on22studiesincludingmorethan6000patients,showsasig-
niﬁcant decrease of preterm delivery and chorioamnionitis
rate in the treated group [29]. Neonatal complications were
also lower in this population [4, 29]. In bacterial vaginosis
associated with pregnancy, antibiotics were found to erad-
icate infection but they showed no eﬀect on the incidence
of preterm delivery [30]. In conclusion, PROM is the only
clinically proved indication for using antibiotics in order to
prevent preterm birth [29].
4. Discussion
There are many possible interventions aiming to treat
this multifactorial syndrome called preterm delivery. As
described here, only some drugs have been proved to be
eﬀective on the contraction process, but there are no clear
evidence of associated improved neonatal outcome. Some
drugsareusedasﬁrst-linesingletherapysuchasβ adrenergic
receptor agonists and atosiban in Europe [11, 12]. In severe
cases, combined therapy could be oﬀered but should be
restricted because of adverse eﬀects addition. A Dutch
prospective study based on 1920 women, reported that the
overall incidence of severe adverse eﬀect is doubled when a
multiple-drug regimen is chosen [27] .T h el i t e r a t u r er e v i e w
evidences that there are still insuﬃcient data regarding
some therapies such as the eﬀectiveness of progesterone in
the absence of previous medical history and the role of
antibiotics, bed rest, and maintenance therapy [5, 31].
Speciﬁc conditions are subject to discussion: in multiple
pregnancies, expanded blood volume and anaemia may
predispose to pulmonary oedema when tocolytic agents such
as β adrenergic receptor agonists, magnesium sulphate, and
calcium channel blockers are prescribed. In these pregnan-
cies, atosiban, with its low side eﬀects incidence, seems
to be the safest choice.
The role of tocolysis in PROM allows pregnancy prolon-
gation for corticosteroids administration but has not been
reported to signiﬁcantly improve neonatal outcome [32]. Is
long-term therapy eﬀective? There is no clinical evidence
on published trials and systematic review to justify tocolytic
therapy maintenance except for atosiban [31].
A critical review about tocolysis points to the potential
risk of delaying preterm delivery specially in case of infec-
tious or inﬂammatory process and does not evidence an
improved neonatal outcome as tocolysis is often associated
with corticosteroids administration [26].
5. Conclusions
Prevalence of preterm birth has increased during the last
decades and it is a real public health concern. Management
with tocolytic drugs aims to stop uterine contractions and
to prevent neonatal risks associated with prematurity by in4 Journal of Pregnancy
Table 1: Eﬀects of currently used tocolytic drugs.
Drugs Eﬀects Outcome Side eﬀects Studies
β AdRA Decrease cAMP Delay D 2–7 days Cardiovascular RCT [5, 11, 12]
Metabolic Meta-analysis [2, 10]
NO donor Increase cGMP Delay D 2 days Cardiovascular Small series [2, 5]
MgSO4 Decrease IC Ca++ No tocolytic eﬀect Neurological RCT, meta-analysis
Metabolic [2, 4–6, 13, 14]
Perinatal mortality
Fetal neuroprotection RCT [15, 16]
PgSI On gap junction Delay D 2–7 days Gastrointestinal RCT, meta-analysis
Decrease IC Ca++ Fetal kidney function [2, 4–6, 17, 18, 26]
Premature closure ductus
arteriosus
Ox RA Competition with receptor
binding Controversial eﬃciency IUGR? Mortality? Review [2]
Few side eﬀects RCT, meta-analysis
[4, 5, 9, 11, 12, 19, 27]
Ca++ CB Decrease IC Ca++ Delay D 7 days Cardiovascular No placebo RCT
Decreased neonatal morbidity Comparative RCT
[2, 4, 9, 20–22]
Progesterone Reduction preterm delivery in high-risk patients RCT [23, 25]
Decrease IC Ca++ Sedative
Decrease Pg synthesis Liver cytolysis [24, 26]
utero transfer of the pregnant patient in a tertiary specialized
centre and by corticosteroids administration [1, 2, 7].
Our review of several studies and meta-analyses reported
on Table 1 conﬁrm the eﬃcacy of β adrenergic receptor
agonists, prostaglandin-synthetase inhibitors, and atosiban
for delaying delivery for 24–48 hours [2, 5, 6, 10, 11, 17].
In terms of maternal and fetal safety, the overall preva-
lence of severe side eﬀects associated with tocolysis is around
1% and is more frequent in multiple therapies, multiple
gestation, and preterm rupture of the membranes [27]. Ato-
siban is our ﬁrst choice drug for safety, followed by pros-
taglandin-synthase inhibitors and nifedipine [2, 5, 6, 12, 27].
For the future, tocolytic drugs development should aim
to reach a better eﬃcacy in terms of pregnancy prolongation
and a lower adverse eﬀects proﬁle. A better understanding of
the regulation of myometrial contractility and the detection
of speciﬁc maternal or fetal parameters should be used for
new tocolytic strategies. Last generation of oxytocin receptor
antagonists such as barusiban could be more eﬃcient and
have less aﬃnity for the vasopressin receptors [9]. Speciﬁc
COX-2 inhibitors or “coxibs,” prostaglandin receptors antag-
onists could be promising tocolytic alternatives [2, 4, 9, 18].
Abbreviations
β AdRA: β adrenergic receptor agonist
MgSO4: Magnesium sulphate
PgSI: Prostaglandin synthase inhibitor
Ox RA: Oxytocin receptor agonist
Ca++ CB: Calcium channel blocker
Delay D: Delay for delivery
RCT: Randomized controlled trial
DA: Ductus arteriosus
IC Ca++: Intracellular calcium concentration
IUGR: Intrauterine growth retardation.
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